Tygacil 50mg (Tigecycline) Pack Of 10 Injections
₨ 23,000
Tygacil 50mg Injection (Tigecycline) is a broad-spectrum glycylcycline antibiotic indicated for the treatment of complicated skin and soft tissue infections (cSSTIs), complicated intra‑abdominal infections (cIAIs), and community‑acquired pneumonia (CAP) when other options aren’t viable. Each vial contains 50 mg of Tigecycline for intravenous infusion, and this pack includes 10 single‑use vials—ideal for hospital settings where multi-dose therapy is required.
Tigecycline works by inhibiting bacterial protein synthesis, targeting a broad range of gram-positive, gram-negative, and anaerobic pathogens—even those resistant to other antibiotics. Doctors typically prescribe Tygacil for hospital-acquired infections, particularly when multidrug-resistant organisms like MRSA, VRE, or ESBL‑producing bacteria are suspected.
Administer Tygacil via slow IV infusion over 30–60 minutes. The initial dose is 100 mg, followed by 50 mg every 12 hours. Dosage may be adjusted for patients with hepatic impairment or severe illness. Healthcare providers administer the treatment in clinical settings with careful monitoring of liver function and signs of bacterial response.
Common side effects include nausea, vomiting, diarrhea, and infusion site reactions. Serious risks like pancreatitis, liver enzyme elevation, or severe arrhythmias require prompt medical attention.
Store vials between 2 °C and 8 °C. Keep them in original packaging to protect from light and moisture. Use within the expiry date and discard unused portions.
Tygacil 50mg Injection (Tigecycline)
Tygacil 50mg Injection contains Tigecycline, a broad-spectrum glycylcycline antibiotic designed for serious bacterial infections in hospitalized patients. It is effective against many drug-resistant bacteria, including strains resistant to tetracyclines, β-lactams, and aminoglycosides.
Indications
- Complicated skin and soft tissue infections (cSSTIs)
- Complicated intra-abdominal infections (cIAIs)
- Community-acquired pneumonia (CAP)
- Multidrug-resistant infections (MRSA, VRE, ESBL-producing organisms)
Dosage & Administration
- Each vial contains 50 mg Tigecycline.
- Initial dose: 100 mg IV, followed by 50 mg IV every 12 hours.
- Infuse over 30–60 minutes.
- Adjust dose for hepatic impairment; consult hospital protocols for pediatric or renal impairment cases.
Mechanism of Action
Tigecycline binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Its structural modifications allow it to evade common resistance mechanisms like efflux pumps and ribosomal protection proteins.
Monitoring & Clinical Use
- Administer under close medical supervision in hospital settings.
- Monitor liver function (ALT/AST), CBCs, and cardiac function (QT interval).
- Evaluate for gastrointestinal side effects and infusion site reactions.
Side Effects of Tygacil 50mg Injection
Common:
- Nausea (30–50%)
- Vomiting
- Diarrhea
- Infusion-related discomfort
Less Common:
- Headache
- Hypertension or hypotension
Serious:
- Pancreatitis
- Hepatic injury (ALT/AST elevations)
- Arrhythmias (QT prolongation)
- Hypersensitivity reactions
Warning: Tygacil carries a black box warning due to a higher risk of mortality compared to other antibiotics. It should only be used when no suitable alternatives are available. Combination therapy may be needed based on culture and sensitivity results.
Storage & Handling of Tygacil 50mg Injection
- Refrigerate vials at 2–8 °C.
- Protect from light and moisture.
- Reconstitute with sterile water or saline before use. Administer promptly.
- Dispose of unused portions per hospital safety protocols.
Tygacil 50mg Injection is a vital treatment for life-threatening, multidrug-resistant infections. Always use under the direction of an infectious disease specialist.
For more hospital-use antibiotics and anti-infective medications, browse our Medicine Category. To explore our full inventory, visit our online pharmacy shop.
Related products
Reviews
Clear filtersThere are no reviews yet.